登錄  |  注冊  |  設為首頁  |  加入收藏  |  聯系我們  |  簡體版

您當前的位置: 首頁>>English >>Research on China Monoclonal Antibody (McAB) Industry, 2014

Research on China Monoclonal Antibody (McAB) Industry, 2014

慧典市場研究報告網(www.hdcmr.com)

Research on China Monoclonal Antibody (McAB) Industry, 2014

  • 【報告編號】: 657305
  • 【最新修訂】: 2014年07月01日
  • 【關 鍵 字】: Monoclonal Antibody (McAB)
  • 【報告頁數】: 60
  • 【報告格式】: 電子版或紙介版
  • 【交付方式】: Email發送或EMS快遞
  • 【價    格】: 紙介版︰$2200    電子版︰$2000
  • 【訂購熱線】: 010-51263229    010-51265563
報告導讀:

報告目錄

查看全部>>

Research on China Monoclonal Antibody (McAB) Industry, 2014

1. Overview of Monoclonal Antibody 
1.1 Definition and Characteristics 
1.2 Preparation Process of Monoclonal Antibody 
1.3 Classification 
1.4 Mechanism of Action 
1.5 Key Technology 

2. Operation Environment of China’s Monoclonal Antibody Industry
2.1 Analysis of Economic Environment 
2.2 Policy Analysis 
2.2.1 Monoclonal Antibody Industry Ranks as a Strategic Emerging Industry
2.2.2 NCCN Guidance Supports Monoclonal Antibody Agents; McAB Agents are Included into Local Health Insurance

3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry
3.1 Development History Overview of International Monoclonal Antibody Market 
3.2 Monoclonal Antibody Agents Listing in Market  
3.3 Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents 
3.4 Powerful Growth Momentum of Global Antibody Market 
3.5 Development Tendency and Outlook of Global Monoclonal Antibody Agents 
3.5.1 Develop Monoclonal Antibody Aiming at New Target Spots 
3.5.2 Diversified Research and Development on Monoclonal Antibody 
3.5.3 Antibody-Drug-Conjugates (ADCs) as a New Research Hotspot and Development Direction 
3.5.4 First Monoclonal Antibody Biological Analogue Approved in European and American Market

4. Operation Situation of China’s Monoclonal Antibody Industry
4.1 Small Market Size 
4.2 Listing Situation of Monoclonal Antibody Agents 
4.3 Comparison of Research Progress between China and Foreign Countries 
4.3.1 China’s Research Progress on Monoclonal Antibody
4.3.2 Differences of New R& D Ability and Industrialization between China and Foreign Countries 
4.4 The First Climax of Monoclonal Antibody: 2017 to 2020

5. China’s Key Monoclonal Antibody Agent Enterprises
5.1 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
5.1.1 Company Profile 
5.1.2 Business Condition 
5.1.3 The Generic Drug of Trastuzumab  Sai Pu Ting Approved for Clinical Use 
5.2 Biotech Pharmaceuticals Co., Ltd. 
5.2.1 Company Profile 
5.2.2 Business Condition 
5.2.3 Production Process 
5.3 Chengdu Huasun Biotechnology Co., Ltd. 
5.3.1 Company Profile 
5.3.2 Representative Products 
5.3.3 Business Condition 
5.4 Zhejiang HISUN Pharmaceutical Co., Ltd. 
5.4.1 Company Profile 
5.4.2 Business Condition 
5.4.3 Progress of R & D
5.5 Shanghai Bio Pharmaceutical Co., Ltd. 
5.5.1 Company Profile 
5.5.2 Business Condition 
5.5.3 Progress of R & D

6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in the Future 
6.1 Enormous China’s Market Space and Potential Medical Demand not Get Satisfied 
6.2 Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market 

報告描述

查看全部>>
Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China’s monoclonal antibody industry.

Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle.

Due to late state, China’s strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries.

According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Huidian Research believes that China’s monoclonal antibody market will embrace its first climax from 2017 to 2020.

相關研究報告

報告搜索

  • 研究報告
  • 免費報告

購買流程

1.選擇報告

ヾ 按行業瀏覽 點擊研究首頁左邊的行業分類 ゝ 按名稱查詢 輸入關鍵字進行站內搜索

2.訂購方式

ヾ 電話購買︰010-51263229 010-51265563 ゝ 在線訂購 點擊您需求的報告在線訂購系統,在您注冊填寫正確的聯系資料後,我們的服務人員會在24小時以內與您取得聯系。 ゞ 郵件定購 發送郵件到︰

3.購買流程

  • (1)確定購買意向電話或網絡確定購買細節
  • (2)簽訂服務合同簽訂研究報告購買合同
  • (3)簽訂服務合同支付報告購買款項
  • (4)購買成功支付報告並售後服務一年

4.匯款信息

開戶名︰北京市北福源信息咨詢有限公司 帳 號︰35090188000014650 開戶行︰光大銀行亞運村支行

手機掃描二維碼區域

版權所有︰慧典市場研究報告網

電話:(86)010-51265563 010-51263229 傳真︰010-84985706   客服郵件︰

京ICP備05012231號-1